Bausch + Lomb at ARVO: 13 Poster Presentations NOV03 XIPERE ARMOR

(PRESS RELEASE)VAUGHAN, ONTARIO, AND LAVAL, QUEBEC — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), announced the presentation of 13 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Denver, Colo., from May 1 … Read more

New Research Reveals Significant Gaps in Consumer Contact Lenses Knowledge

New research commissioned by the Contact Lens Institute (CLI) reveals that US eye care practitioners are missing an opportunity to talk about contact lens options with two out of three patients, among other eye-popping findings. The nationwide survey of nearly 1,000 US adults who require vision correction is part of the organization’s See Tomorrow initiative, … Read more

Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

– Seven abstract presentations showcase ongoing research in presbyopia and glaucoma NORTH CHICAGO, Ill., April 28, 2022 /PRNewswire/ — Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data on VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) … Read more

Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting

13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, ON and LAVAL, QC, April 28, 2022 /CNW/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) … Read more

National Inventors Hall of Fame Announces VoIP and Super Soaker Innovators Among 2022 Class

(PRESS RELEASE) NORTH CANTON, OH — Five innovation pioneers whose inventions range from cataract surgery to the modern automobile will be honored as part of the latest class of National Inventors Hall of Fame (NIHF) Inductees. In partnership with the United States Patent and Trademark Office (USPTO), NIHF will honor these Inductees on May 5, … Read more

Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, April 25, 2022 /CNW/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class … Read more

Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, ON and LAVAL, QC and TRENTON, NJ, April 21, 2022 /CNW/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 48,235,850 million units, or 290,145 pounds, … Read more

Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting

10 Podium Presentations, Two Posters Include Results from the First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) VAUGHAN, ON and LAVAL, QC, April 18, 2022 /CNW/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced the presentation of 10 podium presentations … Read more